Responses
Immune cell therapies and immune cell engineering
Original research
Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.